{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-001328","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.345940+00:00","generated_at":"2026-06-04T14:25:20.160722+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"VolitionRx appoints Dr. Andrew Retter as Chief Medical Officer effective April 1, 2024","bullets":["Dr. Retter is an Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust, London, and dual-registered in Intensive Care and Haematology.","He has advised Volition since January 2022 on Nu.Q® NETs, a CE-marked blood test for sepsis and NETosis-related diseases.","As CMO, he will lead medical strategy and ensure clinical efforts are aligned with patient needs."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-001328","json":"https://secwatch.observer/filing/0001477932-24-001328.json","markdown":"https://secwatch.observer/filing/0001477932-24-001328.md","text":"https://secwatch.observer/filing/0001477932-24-001328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793224001328/0001477932-24-001328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793224001328/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T14:25:20.160722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}